These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37693224)

  • 21. Worse associative memory recall in healthy older adults compared to young ones, a face-name study in Spain and Mexico.
    Flores Vazquez JF; Rubiño J; Contreras López JJ; Siquier A; Cruz Contreras C; Sosa-Ortiz AL; Enriquez Geppert S; Andrés P
    J Clin Exp Neuropsychol; 2021 Aug; 43(6):558-567. PubMed ID: 34538200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity.
    Weigand AJ; Bangen KJ; Thomas KR; Delano-Wood L; Gilbert PE; Brickman AM; Bondi MW;
    Brain Commun; 2020; 2(1):fcz046. PubMed ID: 32051933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.
    Long JM; Coble DW; Xiong C; Schindler SE; Perrin RJ; Gordon BA; Benzinger TLS; Grant E; Fagan AM; Harari O; Cruchaga C; Holtzman DM; Morris JC
    Brain; 2022 Dec; 145(12):4506-4518. PubMed ID: 35867858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the NIH Toolbox Odor Identification Test across normal cognition, amnestic mild cognitive impairment, and dementia due to Alzheimer's disease.
    Echevarria-Cooper SL; Ho EH; Gershon RC; Weintraub S; Kahnt T
    Alzheimers Dement; 2024 Jan; 20(1):288-300. PubMed ID: 37603693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
    Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
    Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The performance of patients with Parkinson's disease on the Face-Name Associative Memory Examination.
    Kormas C; Zalonis I; Evdokimidis I; Potagas C
    Neurol Sci; 2019 Feb; 40(2):405-407. PubMed ID: 30209699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Face name matching and memory complaints in Parkinson's disease.
    Siquier A; Andrés P
    Front Psychol; 2022; 13():1051488. PubMed ID: 36452376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy.
    Sembill JA; Lusse C; Linnerbauer M; Sprügel MI; Mrochen A; Knott M; Engelhorn T; Schmidt MA; Doerfler A; Oberstein TJ; Maler JM; Kornhuber J; Lewczuk P; Rothhammer V; Schwab S; Kuramatsu JB
    Brain Commun; 2023; 5(3):fcad159. PubMed ID: 37389304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
    Vemuri P; Weigand SD; Przybelski SA; Knopman DS; Smith GE; Trojanowski JQ; Shaw LM; Decarli CS; Carmichael O; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Brain; 2011 May; 134(Pt 5):1479-92. PubMed ID: 21478184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of dementia screening tests with biomarkers of Alzheimer's disease.
    Galvin JE; Fagan AM; Holtzman DM; Mintun MA; Morris JC
    Brain; 2010 Nov; 133(11):3290-300. PubMed ID: 20823087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.
    Tosun D; Veitch D; Aisen P; Jack CR; Jagust WJ; Petersen RC; Saykin AJ; Bollinger J; Ovod V; Mawuenyega KG; Bateman RJ; Shaw LM; Trojanowski JQ; Blennow K; Zetterberg H; Weiner MW
    Brain Commun; 2021; 3(2):fcab008. PubMed ID: 33842885
    [No Abstract]   [Full Text] [Related]  

  • 38. Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning.
    Hassenstab J; Chasse R; Grabow P; Benzinger TL; Fagan AM; Xiong C; Jasielec M; Grant E; Morris JC
    Neurobiol Aging; 2016 Jul; 43():23-33. PubMed ID: 27255812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
    Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
    J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting amyloid PET and tau PET stages with plasma biomarkers.
    Jack CR; Wiste HJ; Algeciras-Schimnich A; Figdore DJ; Schwarz CG; Lowe VJ; Ramanan VK; Vemuri P; Mielke MM; Knopman DS; Graff-Radford J; Boeve BF; Kantarci K; Cogswell PM; Senjem ML; Gunter JL; Therneau TM; Petersen RC
    Brain; 2023 May; 146(5):2029-2044. PubMed ID: 36789483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.